Regal Partners Ltd Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Regal Partners Ltd grew its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 21.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,435,956 shares of the biopharmaceutical company's stock after purchasing an additional 258,355 shares during the period. Royalty Pharma comprises approximately 3.7% of Regal Partners Ltd's holdings, making the stock its 9th largest holding. Regal Partners Ltd owned approximately 0.24% of Royalty Pharma worth $36,631,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Brooklyn Investment Group lifted its holdings in shares of Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 876 shares during the period. Allworth Financial LP raised its holdings in shares of Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 877 shares in the last quarter. Riverview Trust Co lifted its stake in Royalty Pharma by 3,953.3% in the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 1,186 shares during the period. Fifth Third Bancorp grew its holdings in Royalty Pharma by 187.1% during the 4th quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 997 shares in the last quarter. Finally, Rakuten Securities Inc. increased its position in Royalty Pharma by 160.5% during the 4th quarter. Rakuten Securities Inc. now owns 1,628 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 1,003 shares during the period. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Stock Up 0.5 %

NASDAQ:RPRX opened at $32.71 on Wednesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The stock has a market capitalization of $18.86 billion, a P/E ratio of 22.56, a P/E/G ratio of 2.31 and a beta of 0.50. The company's 50-day simple moving average is $32.51 and its 200-day simple moving average is $29.50. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, equities analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 2.69%. The ex-dividend date is Friday, May 16th. Royalty Pharma's dividend payout ratio is currently 60.69%.

Wall Street Analyst Weigh In

Separately, Citigroup reaffirmed a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $42.50.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma plc (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.